0001558370-24-006534 8-K 15 20240502 8.01 9.01 20240502 20240502 Annovis Bio, Inc. 0001477845 2834 03 Life Sciences 262540421 DE 1231 8-K 34 001-39202 24907988 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 QR Pharma, Inc. 20091202 8-K 1 anvs-20240502x8k.htm 8-K
0001477845false00014778452024-05-022024-05-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 2, 2024

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware

001-39202

26-2540421

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

101 Lindenwood Drive, Suite 225

Malvern, PA 19355

(Address of Principal Executive Offices, and Zip Code)

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001
per share

ANVS

New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01

Other Events.

As previously announced in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 26, 2024, on April 25, 2024,  Annovis Bio, Inc. (the “Registrant”) entered into a Common Stock Purchase Agreement with an equity line investor (the “Agreement”).  On May 2, 2024 the Parties closed the transactions contemplated by the Agreement. A copy of the opinion of Loeb & Loeb LLP in connection with the issuance of the securities is filed as Exhibit 5.1 hereto.

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

    

Description

5.1

Opinion of Loeb & Loeb LLP

23.1

Consent of Loeb & Loeb LLP (included in Exhibit 5.1)

104

Cover Page Interactive Data File

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANNOVIS BIO, INC.

Date: May 2, 2024

By:

/s/ Maria Maccecchini

Name: Maria Maccecchini

Title: President and Chief Executive Officer

EX-5.1 2 anvs-20240502xex5d1.htm EX-5.1

Exhibit 5.1

Graphic

345 Park Avenue

New York, NY 10154-1895

Direct   212.407.4935
Main     212.407.4000
Fax        212.407.4990 

May 2, 2024

Annovis Bio, Inc.

101 Lindenwood Drive, Suite 225

Malvern, PA 19355

Ladies and Gentlemen:

We have acted as counsel to Annovis Bio, Inc., a Delaware corporation (the “Company”), in connection with the offering by the Company of up to 2,051,428 shares of common stock, $0.0001 par value per share (the “Shares”), pursuant to the (i) Registration Statement on Form S-3 (File No. 333-276814) (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), (ii) prospectus dated February 12, 2024 contained in the Registration Statement (the “Base Prospectus”), and (ii) prospectus supplement dated May 1, 2024 filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations of the Act (together with the Base Prospectus, the “Prospectus”). The Shares are to be issued pursuant to a Common Stock Purchase Agreement dated April 25, 2024 by and between the Company and Keystone Capital Partners, LLC (the “Purchase Agreement”). The Shares are to be sold by the Company as described in the Registration Statement and the Prospectus.

In connection with this opinion, we have examined and relied upon the Registration Statement, the Prospectus and the Purchase Agreement. We have also examined originals or copies, certified or otherwise identified to our satisfaction, of the Company’s certificate of incorporation and bylaws, and such corporate records of the Company and other certificates and documents of officials of the Company, public officials and others as we have deemed appropriate for purposes of this letter. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to authentic original documents of all copies submitted to us as conformed and certified or reproduced copies.

Based upon the foregoing and subject to the assumptions, exceptions, qualifications and limitations set forth hereinafter, we are of the opinion that the Shares have been duly authorized for issuance and, when issued and paid for in accordance with the terms and conditions of the Registration Statement and Prospectus, will be validly issued, fully paid and nonassessable.

In rendering the foregoing opinion, we have assumed that: (i) the Company will issue and deliver the Shares in the manner contemplated by the Registration Statement and the Prospectus; and (ii) the Shares will be issued in compliance with applicable federal and state securities laws.


Annovis Bio, Inc.

May 2, 2024

The opinions we express above are based upon a review only of those laws, statutes, rules, ordinances and regulations which, in our experience, a securities lawyer who is a member of the bar of the State of New York and practicing before the Commission exercising customary professional diligence would reasonably recognize as being applicable to the foregoing transactions. While certain members of this firm are admitted to practice in certain jurisdictions other than New York, in rendering the foregoing opinions we have not examined the laws and we do not express any opinion herein concerning any laws other than the internal laws of the State of New York and the Delaware General Corporation Law or consulted with members of this firm who are admitted in any other We express no opinion herein as to the law of any state or jurisdiction other than the laws of the State of New York, the General Corporation Law of the State of Delaware and the federal laws of the United States of America.

We hereby consent to the filing of this opinion with the Commission as an exhibit to the Current Report on Form 8-K to be filed by the Company in connection with the issuance and sale of the Shares in accordance with the requirements of Item 601(b)(5) of Regulation S−K under the Act and to the reference to our firm therein and in the Prospectus under the caption “Legal Matters.” In giving such consent, we do not thereby admit that this firm is within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission under such Section.

Very truly yours,

/s/ Loeb & Loeb LLP


GRAPHIC 3 anvs-20240502xex5d1001.jpg GRAPHIC begin 644 anvs-20240502xex5d1001.jpg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anvs-20240502.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 anvs-20240502_lab.xml EX-101.LAB EX-101.PRE 6 anvs-20240502_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
May 02, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date May 02, 2024
Entity File Number 001-39202
Entity Registrant Name ANNOVIS BIO, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-2540421
Entity Address State Or Province PA
Entity Address, Address Line One 101 Lindenwood Drive
Entity Address, Adress Line Two Suite 225
Entity Address, City or Town Malvern
Entity Address, Postal Zip Code 19355
City Area Code 484
Local Phone Number 875-3192
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ANVS
Security Exchange Name NYSE
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period true
Entity Central Index Key 0001477845
Amendment Flag false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://annovisbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports anvs-20240502.xsd anvs-20240502_lab.xml anvs-20240502_pre.xml anvs-20240502x8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "anvs-20240502x8k.htm": { "nsprefix": "anvs", "nsuri": "http://annovisbio.com/20240502", "dts": { "schema": { "local": [ "anvs-20240502.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "anvs-20240502_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20240502_pre.xml" ] }, "inline": { "local": [ "anvs-20240502x8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://annovisbio.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_5_2_2024_To_5_2_2024_nP1Lqdzx3UiEovICTeXRQw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20240502x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_2_2024_To_5_2_2024_nP1Lqdzx3UiEovICTeXRQw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20240502x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001558370-24-006534-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-006534-xbrl.zip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end XML 18 anvs-20240502x8k_htm.xml IDEA: XBRL DOCUMENT 0001477845 2024-05-02 2024-05-02 0001477845 false 8-K 2024-05-02 ANNOVIS BIO, INC. DE 001-39202 26-2540421 101 Lindenwood Drive Suite 225 Malvern PA 19355 484 875-3192 Common Stock, par value $0.0001 per share ANVS NYSE false false false false true true